523 related articles for article (PubMed ID: 30561610)
1. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
O'Donoghue ML; Fazio S; Giugliano RP; Stroes ESG; Kanevsky E; Gouni-Berthold I; Im K; Lira Pineda A; Wasserman SM; Češka R; Ezhov MV; Jukema JW; Jensen HK; Tokgözoğlu SL; Mach F; Huber K; Sever PS; Keech AC; Pedersen TR; Sabatine MS
Circulation; 2019 Mar; 139(12):1483-1492. PubMed ID: 30586750
[TBL] [Abstract][Full Text] [Related]
3. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
Shapiro MD; Minnier J; Tavori H; Kassahun H; Flower A; Somaratne R; Fazio S
J Am Heart Assoc; 2019 Feb; 8(4):e010932. PubMed ID: 30755061
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).
Zhang X; Stiekema LCA; Stroes ESG; Groen AK
Lipids Health Dis; 2020 May; 19(1):91. PubMed ID: 32393252
[TBL] [Abstract][Full Text] [Related]
5. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
[TBL] [Abstract][Full Text] [Related]
6. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
7. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Marston NA; Gurmu Y; Melloni GEM; Bonaca M; Gencer B; Sever PS; Pedersen TR; Keech AC; Roselli C; Lubitz SA; Ellinor PT; O'Donoghue ML; Giugliano RP; Ruff CT; Sabatine MS
Circulation; 2020 May; 141(20):1600-1607. PubMed ID: 32223429
[TBL] [Abstract][Full Text] [Related]
8. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Giugliano RP; Pedersen TR; Saver JL; Sever PS; Keech AC; Bohula EA; Murphy SA; Wasserman SM; Honarpour N; Wang H; Lira Pineda A; Sabatine MS;
Stroke; 2020 May; 51(5):1546-1554. PubMed ID: 32312223
[TBL] [Abstract][Full Text] [Related]
9. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
10. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
[TBL] [Abstract][Full Text] [Related]
11. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.
Bergmark BA; O'Donoghue ML; Murphy SA; Kuder JF; Ezhov MV; Ceška R; Gouni-Berthold I; Jensen HK; Tokgozoglu SL; Mach F; Huber K; Gaciong Z; Lewis BS; Schiele F; Jukema JW; Pedersen TR; Giugliano RP; Sabatine MS
JAMA Cardiol; 2020 Jun; 5(6):709-713. PubMed ID: 32347887
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
14. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
[TBL] [Abstract][Full Text] [Related]
15. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
[TBL] [Abstract][Full Text] [Related]
16. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
[TBL] [Abstract][Full Text] [Related]
17. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
[TBL] [Abstract][Full Text] [Related]
18. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
19. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Watts GF; Chan DC; Somaratne R; Wasserman SM; Scott R; Marcovina SM; Barrett PHR
Eur Heart J; 2018 Jul; 39(27):2577-2585. PubMed ID: 29566128
[TBL] [Abstract][Full Text] [Related]
20. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.
Mahmood T; Minnier J; Ito MK; Li QH; Koren A; Kam IW; Fazio S; Shapiro MD
Eur J Prev Cardiol; 2021 Jul; 28(8):816-822. PubMed ID: 34298554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]